- Organizations: Alcon, Inc.
Products
Alcon launches first fully personalized LASIK treatment
The wavelight plus includes ray-tracing technology to create a 3D eye model for a fully-tailored treatment approach for refractive surgery.
Business
Alcon officially purchases LumiThera
Acquisition of the Valeda Light Delivery System includes plans to expand commercial market availability in 2026.
Business
Alcon to acquire STAAR Surgical
The $1.5 billion deal includes STAAR’s FDA-approved implantable collamer lenses; expected to close within 6 to 12 months.
Products
Alcon's TRYPTYR launches to the US market
Company’s first-in-class, prescription-based pharmaceutical features acoltremon, making it the first topical neuromodulator to rapidly increase tear production for DED.
Business
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions
Check out the latest leadership news from the eyecare space, including a new CEO at ViaLase and a leading optometrist joining myze.Business
Alcon to purchase LumiThera
Targeting a Q3 sale, acquisition includes Valeda Light Delivery System, the first and only PBM treatment for early-to-intermediate dry AMD.
Events
Alcon offers first look at TRYPTYR, debuts new innovations for contact lens ordering app
Company announces partnership with Revolution EHR to advance its MARLO platform; highlights new dry eye and contact lens offerings.Products
FDA approves Alcon's TRYPTYR (acoltremon ophthalmic solution) 0.003% for DED
The prescription-based eye drop is the first that stimulates corneal nerves to directly address tear deficiency; company plans for a Q3 2025 U.S. launch.
Products
Alcon debuts new digital platform for clinics and surgery centers
Designed for use within the Alcon Vision Suite, this cloud-based platform connects clinics’ patient and surgery data to a surgery center.
Products
Alcon launches UNITY vitreoretinal and cataract surgery systems
Debuting at ASCRS, the UNITY Vitreoretinal Cataract and Cataract stand-alone systems expand the Alcon Vision Suite of surgical technologies.
Pipeline
Long-term data finds acoltremon 0.003% increases tear production in DED
Presented at ASCRS, phase 3 COMET-4 results show AR-15512 provides a rapid onset and sustained improvement over 12 months.
Products
Alcon launches Clareon PanOptix Pro IOL in the US
With a broad commercial rollout planned for next month, this will be the company’s first presbyopia-correcting IOL available in its Clareon AutonoMe preloaded system.
Business
Alcon purchases majority stake in Aurion Biotech
Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.
Business
Alcon to acquire Lensar and its next-gen FLACS portfolio
Deal includes the ALLY Robotic Cataract Laser System, the first FDA-cleared platform to enable femtosecond-laser-assisted cataract surgery.
Products
Alcon launches Systane Pro PF drops for dry eye
Over-the-counter artificial tear is marketed as the “longest lasting eye drop” in the company’s SYSTANE portfolio.
Products
Alcon launches Voyager DSLT in the US
Device is the first and only FDA-cleared DSLT laser for glaucoma to deliver laser energy via a non-contact approach through the cornea.
Events
Eyecare companies offering support to LA wildfire victims
Industry leaders such as CooperVision, Alcon, Bausch + Lomb, and EssilorLuxottica are providing supplies and services to optometrists and residents in need.
Products
Alcon voluntarily recalls Systane Lubricant Eye Drops Ultra PF
Late last month, the FDA reported a potential risk for fungal contamination associated with one lot of the preservative-free eye drops.
Products
Alcon unveils Total30 for Astigmatism expanded parameters
New additions to the first and only reusable monthly lens feature key technologies for optimal comfort and a 2.75D cylinder.
Products